Use of capecitabine in management of early colon cancer
H Hameed, J CassidyBeatson West of Scotland Cancer Centre, Glasgow, Scotland, UKAbstract: Capecitabine (Xeloda®, Roche, Basel, Switzerland) is a pro-drug of 5-fluorouracil (5-FU), and it is converted to 5-FU in the cancer cell by enzymatic degradation. The role of capecitabine in colorec...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2011-08-01
|
| Series: | Cancer Management and Research |
| Online Access: | http://www.dovepress.com/use-of-capecitabine-in-management-of-early-colon-cancer-a8108 |